Amneal Pharmaceuticals (NASDAQ:AMRX) Announces Earnings Results, Misses Estimates By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) issued its quarterly earnings results on Friday. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03), RTT News reports. The business had revenue of $730.52 million during the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same period in the prior year, the company posted $0.14 EPS. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.700 EPS.

Amneal Pharmaceuticals Stock Up 3.5 %

Shares of NASDAQ AMRX opened at $8.67 on Friday. The stock’s 50 day moving average price is $8.10 and its two-hundred day moving average price is $8.32. The stock has a market capitalization of $2.69 billion, a P/E ratio of -12.75 and a beta of 1.10. Amneal Pharmaceuticals has a 52-week low of $5.01 and a 52-week high of $9.48.

Analyst Upgrades and Downgrades

AMRX has been the subject of a number of analyst reports. Piper Sandler increased their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.60.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 62,590 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90. Following the sale, the director now directly owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. This represents a 3.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 160,000 shares of company stock worth $1,292,000. 26.56% of the stock is currently owned by company insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.